title: The function and significance of SELENBP1 downregulation in human bronchial epithelial carcinogenic process.
abstract: BACKGROUND
  Our quantitative proteomic study showed that selenium-binding protein 1 (SELENBP1) was progressively decreased in human bronchial epithelial carcinogenic process. However, there is little information on expression and function of SELENBP1 during human lung squamous cell cancer (LSCC) carcinogenesis.
  
  
  METHODS
  iTRAQ-tagging combined with 2D LC-MS/MS analysis was used to identify differentially expressed proteins in the human bronchial epithelial carcinogenic process. SELENBP1, member of selenoproteins family and progressively downregulated in this process, was selected to further study. Both Western blotting and immunohistochemistry were performed to detect SELENBP1 expression in independent sets of tissues of bronchial epithelial carcinogenesis, and ability of SELENBP1 for discriminating NBE (normal bronchial epithelium) from preneoplastic lesions from invasive LSCC was evaluated. The effects of SELENBP1 downregulation on the susceptibility of benzo(a)pyrene (B[a]P)-induced human bronchial epithelial cell transformation were determined.
  
  
  RESULTS
  102 differentially expressed proteins were identified by quantitative proteomics, and SELENBP1 was found and confirmed being progressively decreased in the human bronchial epithelial carcinogenic process. The sensitivity and specificity of SELENBP1 were 80% and 79% in discriminating NBE from preneoplastic lesions, 79% and 82% in discriminating NBE from invasive LSCC, and 77% and 71% in discriminating preneoplastic lesions from invasive LSCC, respectively. Furthermore, knockdown of SELENBP1 in immortalized human bronchial epithelial cell line 16HBE cells significantly increased the efficiency of B[a]P-induced cell transformation.
  
  
  CONCLUSIONS
  The present data shows for the first time that decreased SELENBP1 is an early event in LSCC, increases B[a]P-induced human bronchial epithelial cell transformation, and might serve as a novel potential biomarker for early detection of LSCC.
authors: Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan, China ; School of Nursing, University of South China, Hengyang, Hunan, China.
authors: Gu-Qing
authors: GQ
authors: Zeng
authors: Hong
authors: H
authors: Yi
authors: Peng-Fei
authors: PF
authors: Zhang
authors: Xin-Hui
authors: XH
authors: Li
authors: Rong
authors: R
authors: Hu
authors: Mao-Yu
authors: MY
authors: Li
authors: Cui
authors: C
authors: Li
authors: Jia-Quan
authors: JQ
authors: Qu
authors: Xingming
authors: X
authors: Deng
authors: Zhi-Qiang
authors: ZQ
authors: Xiao
mesh_terms: D000595:Amino Acid Sequence; D017209:Apoptosis; D001980:Bronchi / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002453:Cell Cycle; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism*; D015536:Down-Regulation; D004847:Epithelial Cells / Q000378:metabolism / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic; D055786:Gene Knockout Techniques; D006801:Humans; D061346:Laser Capture Microdissection; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008969:Molecular Sequence Data; D020543:Proteome / Q000235:genetics / Q000378:metabolism; D012372:ROC Curve; D020545:Respiratory Mucosa / Q000473:pathology; D051137:Selenium-Binding Proteins / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D053719:Tandem Mass Spectrometry
chemical_list: D020543:Proteome; C495175:SELENBP1 protein, human; D051137:Selenium-Binding Proteins
references: PLoS One. 2009 Nov 16;4(11):e7774
references: 19924303
references: Cancer Res. 1998 Jul 15;58(14):3150-3
references: 9679983
references: Int J Cancer. 2006 May 15;118(10):2433-40
references: 16380993
references: Clin Cancer Res. 2008 Jan 15;14(2):435-45
references: 18223218
references: J Pathol. 2004 Mar;202(3):321-9
references: 14991897
references: Prev Med. 1997 Jul-Aug;26(4):427-34
references: 9245661
references: Biochem Biophys Res Commun. 2009 Feb 6;379(2):583-8
references: 19118533
references: Cancer Res. 2010 May 1;70(9):3450-62
references: 20406978
references: Anticancer Res. 2006 Mar-Apr;26(2A):899-904
references: 16619485
references: Crit Rev Biotechnol. 2009;29(1):10-7
references: 19514899
references: Cancer. 1987 Jul 15;60(2):145-8
references: 3594351
references: Mol Cell Proteomics. 2012 Jun;11(6):M111.013946
references: 22298307
references: Br J Cancer. 2004 Jun 1;90(11):2157-66
references: 15150609
references: Oncogene. 2002 May 23;21(23):3663-9
references: 12032834
references: Mutat Res. 2001 Apr 18;475(1-2):123-39
references: 11295158
references: Oncogene. 2002 Oct 21;21(48):7421-34
references: 12379883
references: J Biol Chem. 2000 May 12;275(19):14457-65
references: 10799528
references: J Biol Chem. 2010 Apr 16;285(16):12055-62
references: 20157118
references: Annu Rev Nutr. 2001;21:453-73
references: 11375445
references: Mol Nutr Food Res. 2008 Nov;52(11):1289-99
references: 18435490
references: J Natl Cancer Inst. 2001 Jun 6;93(11):824-42
references: 11390532
references: Ann N Y Acad Sci. 2004 Dec;1031:234-41
references: 15753149
references: Respir Res. 2002;3:20
references: 11980589
references: J Biol Chem. 2010 Oct 22;285(43):33010-33017
references: 20709753
references: Proc Nutr Soc. 2005 Nov;64(4):527-42
references: 16313696
references: N Engl J Med. 1979 Feb 22;300(8):381-5
references: 759914
references: Lancet Oncol. 2001 Sep;2(9):533-43
references: 11905707